

Recent findings and future directions for the intersection of genetic and environmental contributions to schizophrenia

© The Author(s), 2024. This article is under exclusive and permanent license to Genomic Press

Genomic Psychiatry May 2025;1(3):17–21; doi: <https://doi.org/10.61373/gp024v.0055>

Keywords: Schizophrenia, genetic risk score, risk factors, gene environment interaction

It is well established that both genetic and environmental factors contribute to risk for schizophrenia (SCZ), and much progress has been made in identifying the specific factors conferring risk. However, the nature and extent of interactions between them has long been a topic of debate. Both the data and methods available to address this have evolved rapidly, enabling new prospects for identifying gene–environment interactions in SCZ. To date, there is limited evidence of strong gene–environment interactions, with environmental factors, molecular genetic risk, and family history simultaneously contributing to risk of SCZ. Still, there are several enduring challenges, some of which can likely be addressed with new tools, methods, and approaches for investigating gene–environment interplay. Consequently, advancements in this field will enhance our capacity to identify individuals most vulnerable to specific environmental exposures, which is pivotal for targeted prevention and intervention.

Recent Findings from Molecular Genetics Studies

Family, twin, and adoption studies robustly support the role of genetic factors in schizophrenia (SCZ) (1–4). While early attempts to identify specific genetic markers through candidate gene studies faced challenges in reproducibility, these studies highlighted the importance of properly controlling for multiple testing to reduce the risk of false positives, as well as the need for large samples to detect variants with small effect sizes (5, 6). In the past 15 years, genome-wide association studies (GWAS) and the subsequent cascade of downstream analyses have made great strides in elucidating the genetic foundations of SCZ. Large-scale international collaborations have been instrumental in pooling resources, with the latest study amassing over 76,000 SCZ cases, and this has facilitated comprehensive investigation into the genetic basis of SCZ (7). It is now clear that SCZ is highly polygenic, with risk stemming from the cumulative influence of common and rare variants with small to moderate effect sizes (odds ratios 0.78–1.24) (7), and rare copy-number variants with strong effects (2 to >60x higher risk) (8, 9).

Concomitant with the emergence of genetic associations of high-confidence with SCZ, polygenic risk scores (PRS) were developed to quantify a person's predisposition for a disorder which is attributable to the additive impact of multiple common genetic variants (10). This risk is expressed as a single score, with single nucleotide polymorphisms (SNPs) weighted by their effect sizes from GWAS. SCZ-PRS offers a statistically significant but modest level of prediction and has been used to explore nosology and establish common genetic underpinnings with other psychiatric and somatic disorders (11). PRS methodologies are continually refined to enhance predictive power and improve performance across diverse populations (12, 13).

Established and Emerging Environmental Risk Factors

The majority of SCZ risk stems from genetic effects but 19%–36% of the risk arises from environmental sources (1, 2). Several environmental risk factors for SCZ have been consistently identified in large-scale epidemiological studies, including cannabis use, pregnancy and birth complications, infections, winter birth, migration, urban upbringing, stressful life events, and childhood adversity (14–17). Air pollution is an emerging risk factor (18) that is complex and typically entwined with social inequality, and there are likely other unexplored environmental and chemical-based risk factors awaiting discovery. While the prevalence of these environmental factors varies across populations, they often disproportionately affect more disadvantaged groups. Some of the identified risk factors are quite common, for instance, childhood adversity (which encompasses parental separation) and adverse perinatal factors each have a population prevalence of ~40% in modern western cohorts (19, 20). Despite the widespread occurrence of environmental risk factors, only a subset of exposed individuals develops SCZ, which strongly suggests differential sensitivity due to underlying genetic predisposition.

Investigations of environmental risk have predominantly involved pursuing individual risk factors in a hypothesis-driven manner, somewhat echoing the early genetic approaches. Just as genetic risk exerts effects through the cumulative impact of multiple genetic factors, it has been proposed that environmental risk may similarly arise from accumulated exposure to a range of adverse environmental factors (21). Over the life course, individuals are subjected to myriad interconnected environmental exposures at different developmental stages, each potentially having protective, neutral, or negative impacts on psychiatric risk. This concept, termed the “exposome,” encompasses the entirety of environmental exposures from conception onward (21).

Mirroring PRS approaches, there have been attempts to generate an exposome score weighted by the effect sizes of the environmental factors for SCZ phenotypes (22–25). Unlike genetic studies, which typically require only a single blood sample to derive genetic risk, exposome research requires richly phenotyped, longitudinal, population-based cohorts. While this research is still in early stages, there is optimism that embracing the complexity and dynamic nature of environmental exposures will deliver further elucidation of their collective influence on SCZ.

Is Gene-Environment Interplay the Missing Link?

Exploring gene-environment interplay, which encompasses both gene-environment correlation (where genotype influences exposure to environmental factors, termed rGE) and gene-environment interaction (where the effect of the genotype depends on the presence of an environmental factor, or vice versa, termed $G \times E$), holds promise for gaining further insight into the etiology of SCZ.

The SNP-based heritability of SCZ identified in GWAS accounts for ~24% of the variance, a stark contrast to the estimates of ~80% from twin studies (2, 4, 7). While rare genetic variation accounts for some of





the discrepancy, $G \times E$ has been theorized to at least partially explain this heritability gap, and this is supported by one recent study (26).

Early $G \times E$ studies in SCZ relied on proxies such as family history for genetic risk assessment, or examined single candidate genes, as summarized by earlier reviews (17, 27, 28). These studies encountered similar power issues and biases as candidate gene association studies and often failed to replicate. Genome-wide approaches are considered superior to hypothesis-driven methods for genetic associations but require prohibitively large samples for $G \times E$ studies. Therefore, gene prioritization strategies are essential. In one successful example, a genome-wide environment interaction study used a two-stage design to reveal a significant interaction between *in utero* exposure to cytomegalovirus infection and a variant within the *CTNNA3* gene (29). First, the association between the exposure and the complete set of SNPs was assessed, then these prioritized SNPs were examined further to identify interaction effects for the outcome. This variant was not previously linked to SCZ, and this interaction was subsequently replicated (30).

In recent years, a few studies have investigated $G \times E$ interactions using PRS as an indicator of genetic liability to SCZ. Most of these studies report independent effects of PRS and environmental exposures and no evidence for multiplicative interactions, including for infections (31), adverse perinatal factors (32, 33), and childhood adversity (34). One study found evidence for an additive interaction effect between SCZ-PRS and childhood adversity on psychosis phenotypes—but it was mediated by a measure of affective dysregulation (35). Even for cannabis use, which demonstrates modest genetic correlations with SCZ (36–38), $G \times E$ studies report null interactions. Similarly, for urbanicity, studies support a degree of rGE (39, 40), but null interaction effects for birth in densely populated areas on SCZ risk (41). Still, large-scale genetic studies have rarely considered the impact of variation in environmental risk, highlighting the need for further research in this area.

On the other hand, positive additive interactions have been observed between dichotomized SCZ-PRS and certain environmental factors such as lifetime regular cannabis use and early-life adversities (42). These findings suggest a synergistic effect, indicating that the combined influence of genetic predisposition and environmental exposure exceeds the sum of their individual effects. There was no evidence of interaction effects for winter birth, hearing impairment, or child abuse. Positive additive interactions have also been identified for exposome risk scores and SCZ-PRS for SCZ spectrum disorders (24, 43, 44). Still, there is the need for confirmatory studies in large cohorts and different populations.

Presently, findings from PRS studies do not support the classic $G \times E$ (multiplicative) interaction model, whereby genotype and environmental factors only exert effects when both are present. Instead, current evidence suggests that genetic and environmental factors both contribute to risk through either independent or additive effects. However, statistical considerations for detecting and interpreting $G \times E$ interactions, such as choice of scale and model selection, are often overlooked. These issues have been extensively discussed, with recommendations for best practice (45, 46). Furthermore, it would be premature to entirely reject $G \times E$ hypotheses on the basis of PRS, which capture only a small portion of the expected genetic liability, among other methodological limitations (47, 48).

Future Focus

The extent to which there is interplay between genetic, familial, and environmental factors in the development of SCZ is still largely unknown. While we now possess a wealth of data on genetic and environmental risk factors, the challenge lies in making connections between them and then translating findings into clinically useful insights.

Challenges with GWAS and PRS Studies

Although findings from GWAS have provided useful biological insights into SCZ, they have yet to translate into tangible improvements in diagnosis and treatment. Despite their powerful impact on research, PRS have little clinical utility. Moreover, variations between the top and bottom percentiles might be exaggerated due to the case-control design of GWAS, with more modest risk prediction found in other real-world settings such as electronic health records (49). Assortative mating and rGE

can also contribute to inflation of GWAS estimates (50). To address this, family-based GWAS designs have been utilized for several disorders by constructing PRS from non-transmitted parental alleles, albeit not yet implemented for SCZ (51). These designs can help identify rare variants and provide less biased estimates of direct genetic effects by reducing confounding from assortative mating and population stratification (51); however, they pose challenges in terms of recruitment of family members of individuals with SCZ, acquiring informed consent, and limited statistical power.

As GWAS sample sizes have increased, so has the proportion of the variance explained by PRS, nevertheless a ceiling effect is impending, whereby further increases in sample size will yield diminishing returns in explanatory power (52). However, these scores may have other useful applications, through correlations with symptoms and clinical features they may prove valuable in distinguishing between psychiatric disorders and optimal treatment approaches (53, 54).

Expanding the Analytical Toolkit

Although they minimize the multiple testing burden, PRS are likely too broad to be useful for more specific $G \times E$ interactions, necessitating more focused approaches and methodological tools. For instance, two-step designs which reduce the initial pool of target SNPs are a resourceful way to circumnavigate the prohibitive multiple testing burden (29, 55, 56). Fine-mapping methods reduce GWAS-derived loci to a smaller set of likely causal variants and can aid prioritization of genes for downstream $G \times E$ analyses (7). Modified PRS approaches endeavor to enhance polygenic risk prediction by leveraging correlated phenotypes (57), while others focus on enrichment of genetic variants at the biological pathway level (58).

Beyond genomics, various omics technologies have been applied to examine different aspects of SCZ pathogenesis and may yield further insights about the intermediary paths between genotype and environmental factors (59). These advancements offer novel avenues for capturing genetic risk and biomarkers for downstream application in gene-environment studies.

Other Sources of Genetic Variation

While recent focus has been on identifying common genetic variants associated with SCZ, rare genetic variants remain relatively unexplored in the context of $G \times E$ interactions. Only recently have large-scale collaborations, like the Schizophrenia Exome Sequencing Meta-Analysis (SCHEMA) consortium, amassed sufficient sequence data from many studies to identify rare genetic variants with exome-wide significance. The study identified ultra-rare coding variants in 10 genes with strong effect sizes (odds ratios 3–50, $P < 2.14 \times 10^{-6}$) and overlapping findings with the most recent GWAS (60). However, several rare copy-number variations (CNVs), involving deletions or duplications of large segments of DNA, have been identified which can have substantial impact on risk of SCZ. Individuals carrying associated CNVs, such as the 22q11.2 deletion, may be more likely to be exposed to adverse environmental exposures due to the impact on medical, social, and cognitive aspects (61). It has been reported that lifetime stress may influence psychosis risk symptoms in 22q11.2 deletion carriers, suggesting that it may be worth further investigating the role of environmental factors in the expression of psychosis risk among those with CNVs (62). Rare variants could be a promising avenue of exploration in a precision medicine context given that they are a single locus of strong effect, yet their rarity poses methodological challenges in terms of garnering adequate statistical power for scientific investigation. The scarcity of $G \times E$ studies using rare variants limits the field's current comprehension of the genetic component of the interaction.

The spotlight on molecular methodologies in human genetics should not overlook the significance of familial phenotypic records in genetic medicine and genetic epidemiology (63). There are several recent and emerging methods for model-based estimates of liability from family records, such as family genetic risk scores (FGRS) (64), the liability threshold on family history (LT-FH) (65), and Pearson-Aitken family genetic risk scores (PA-FGRS) (66). FGRS have already been used to evaluate



diagnostic stability, genetic architecture, and clinical features of several psychiatric disorders (67, 68). Although counterintuitive, PRS and indicators of family history have low correlations and appear to contribute independently to SCZ prediction (66).

Increasing Ancestral Diversity

The overwhelming majority of molecular genetic studies have been conducted in populations of European ancestry, potentially exacerbating health inequalities and impeding scientific progress (69). Several initiatives are underway to diversify these samples (7, 70), which will provide opportunities to increase our understanding of genetic risk across different environments, cultures, and ancestries.

As with the genetic findings, the bulk of the reliable evidence on environmental risk factors primarily stems from European and North American studies. Nordic registers, documenting numerous medical, social and demographic factors for the entire population from birth, are a rich resource for investigating the impact of environmental risk factors in rare psychiatric disorders and have provided some of the most robust epidemiological estimates (20, 71, 72).

Exploring more diverse settings and countries with greater environmental variability will likely clarify whether there are key cultural differences and aid understanding of true etiological associations. The challenge persists that to comprehensively investigate the genetic and environmental contributions to SCZ requires the rare combination of large, genotyped cohorts with longitudinal assessments of several environmental exposures over the life course.

Conclusion

There is still much to uncover regarding the interplay between genetic, familial, and environmental factors in SCZ. Undoubtedly, there are additional environmental factors and gene-environment interactions yet to be discovered. Given the high degree of shared genetic and environmental risk among psychiatric disorders, exploring $G \times E$ may help to isolate disorder-specific associations and pinpoint mediating or moderating biological pathways. Advancements in genetic and statistical tools will likely accelerate $G \times E$ research and maximize the utilization of existing datasets. The prospect of identifying individuals most vulnerable to specific environmental exposures underscores the importance of further exploration, offering opportunities for prevention and intervention.

Acknowledgments

This publication was supported by the National Institute of Mental Health of the National Institutes of Health under award number # R01 MH122544 (PI: Bergen). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Natassia Robinson, PhD¹ , and Sarah E. Bergen, PhD¹ 

¹ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 171 65 Stockholm, Sweden
✉ e-mail: sbergen@gmail.com

References

- Lichtenstein P, Yip BH, Björk C, Pawitan Y, Cannon TD, Sullivan PF, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. *Lancet*. 2009;373(9659):234–9. DOI: [10.1016/S0140-6736\(09\)60072-6](https://doi.org/10.1016/S0140-6736(09)60072-6). PMID: 19150704; PMCID: [PMC3879718](https://pubmed.ncbi.nlm.nih.gov/PMC3879718/)
- Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. *Arch Gen Psychiatry*. 2003;60(12):1187–92. DOI: [10.1001/archpsyc.60.12.1187](https://doi.org/10.1001/archpsyc.60.12.1187). PMID: 14662550
- Kendler KS. What psychiatric genetics has taught us about the nature of psychiatric illness and what is left to learn. *Mol Psychiatry*. 2013;18(10):1058–66. DOI: [10.1038/mp.2013.50](https://doi.org/10.1038/mp.2013.50). PMID: 23628988
- Hilker R, Helenius D, Fagerlund B, Skytté A, Christensen K, Werge TM, et al. Heritability of schizophrenia and schizophrenia spectrum based on the nationwide danish twin register. *Biol Psychiatry*. 2018;83(6):492–8. DOI: [10.1016/j.biopsych.2017.08.017](https://doi.org/10.1016/j.biopsych.2017.08.017). PMID: 28987712
- Johnson EC, Border R, Melroy-Greif WE, de Leeuw CA, Ehringer MA, Keller MC. No evidence that schizophrenia candidate genes are more associated with schizophre-

- nia than noncandidate genes. *Biol Psychiatry*. 2017;82(10):702–8. DOI: [10.1016/j.biopsych.2017.06.033](https://doi.org/10.1016/j.biopsych.2017.06.033). PMID: 28823710; PMCID: [PMC5643230](https://pubmed.ncbi.nlm.nih.gov/PMC5643230/)
- Colhoun HM, McKeigue PM, Smith GD. Problems of reporting genetic associations with complex outcomes. *Lancet*. 2003;361(9360):865–72. DOI: [10.1016/S0140-6736\(03\)12715-8](https://doi.org/10.1016/S0140-6736(03)12715-8). PMID: 12642066
- Trubetskoy V, Pardifias AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature*. 2022;604(7906):502–8. DOI: [10.1038/s41586-022-04434-5](https://doi.org/10.1038/s41586-022-04434-5). PMID: 35396580; PMCID: [PMC9392466](https://pubmed.ncbi.nlm.nih.gov/PMC9392466/)
- Rees E, Kirov G. Copy number variation and neuropsychiatric illness. *Curr Opin Genet Dev*. 2021;68:57–63. DOI: [10.1016/j.gde.2021.02.014](https://doi.org/10.1016/j.gde.2021.02.014). PMID: 33752146; PMCID: [PMC8219524](https://pubmed.ncbi.nlm.nih.gov/PMC8219524/)
- Marshall CR, Howrigan DP, Merico D, Thiruvahindrapuram B, Wu W, Greer DS, et al. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. *Nat Genet*. 2017;49(1):27–35. DOI: [10.1038/ng.3725](https://doi.org/10.1038/ng.3725). PMID: 27869829; PMCID: [PMC5737772](https://pubmed.ncbi.nlm.nih.gov/PMC5737772/)
- International Schizophrenia Consortium, Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature*. 2009;460(7256):748–52. DOI: [10.1038/nature08185](https://doi.org/10.1038/nature08185). PMID: 19571811; PMCID: [PMC3912837](https://pubmed.ncbi.nlm.nih.gov/PMC3912837/)
- Lewis CM, Vassos E. Polygenic scores in psychiatry: on the road from discovery to implementation. *Am J Psychiatry*. 2022;179(11):800–6. DOI: [10.1176/appi.ajp.20220795](https://doi.org/10.1176/appi.ajp.20220795). PMID: 36317334
- Kachuri L, Chatterjee N, Hirbo J, Schaid DJ, Martin I, Kullo IJ, et al. Principles and methods for transferring polygenic risk scores across global populations. *Nat Rev Genet*. 2024;25(1):8–25. DOI: [10.1038/s41576-023-00637-2](https://doi.org/10.1038/s41576-023-00637-2). PMID: 37620596; PMCID: [PMC10961971](https://pubmed.ncbi.nlm.nih.gov/PMC10961971/)
- Choi SW, Mak TS-H, O'Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. *Nat Protoc*. 2020;15(9):2759–72. DOI: [10.1038/s41596-020-0353-1](https://doi.org/10.1038/s41596-020-0353-1). PMID: 32709988; PMCID: [PMC7612115](https://pubmed.ncbi.nlm.nih.gov/PMC7612115/)
- Vassos E, Agerbo E, Mors O, Pedersen CB. Urban-rural differences in incidence rates of psychiatric disorders in Denmark. *Br J Psychiatry*. 2016;208(5):435–40. DOI: [10.1192/bjp.bp.114.161091](https://doi.org/10.1192/bjp.bp.114.161091). PMID: 26678865
- Brown AS. The environment and susceptibility to schizophrenia. *Pro Neurobiol*. 2011;93(1):23–58. DOI: [10.1016/j.pneurobio.2010.09.003](https://doi.org/10.1016/j.pneurobio.2010.09.003). PMID: 20955757; PMCID: [PMC3521525](https://pubmed.ncbi.nlm.nih.gov/PMC3521525/)
- Belbasis L, Köhler CA, Stefanis N, van Os J, Vieta E, Seeman MV, et al. Risk factors and peripheral biomarkers for schizophrenia spectrum disorders: an umbrella review of meta-analyses. *Acta Psychiatr Scand*. 2018;137(2):88–97. DOI: [10.1111/acps.12847](https://doi.org/10.1111/acps.12847). PMID: 29288491
- Robinson N, Bergen SE. Environmental risk factors for schizophrenia and bipolar disorder and their relationship to genetic risk: current knowledge and future directions. *Front Genet*. 2021;12:686666. DOI: [10.3389/fgene.2021.686666](https://doi.org/10.3389/fgene.2021.686666). PMID: 34262598; PMCID: [PMC8273311](https://pubmed.ncbi.nlm.nih.gov/PMC8273311/)
- Khan A, Plana-Ripoll O, Antonsen S, Brandt J, Geels C, Landecker H, et al. Environmental pollution is associated with increased risk of psychiatric disorders in the US and Denmark. *PLoS Biol*. 2019;17(8):e3000353. DOI: [10.1371/journal.pbio.3000353](https://doi.org/10.1371/journal.pbio.3000353). PMID: 31430271; PMCID: [PMC6701746](https://pubmed.ncbi.nlm.nih.gov/PMC6701746/)
- Robinson N, Ploner A, Leone M, Lichtenstein P, Kendler KS, Bergen SE. Impact of early-life factors on risk for schizophrenia and bipolar disorder. *Schiz Bull*. 2023;49(3):768–77. DOI: [10.1093/schbul/sbac205](https://doi.org/10.1093/schbul/sbac205). PMID: 36946500; PMCID: [PMC10154720](https://pubmed.ncbi.nlm.nih.gov/PMC10154720/)
- Robinson N, Ploner A, Leone M, Lichtenstein P, Kendler KS, Bergen SE. Environmental risk factors for schizophrenia and bipolar disorder from childhood to diagnosis: a swedish nested case-control study. *Psychol Med*. 2024;1–10. DOI: [10.1017/S0033291724000266](https://doi.org/10.1017/S0033291724000266). PMID: 38425272
- Erzin G, Gülöksüz S. The exposome paradigm to understand the environmental origins of mental disorders. *Alpha Psychiatry*. 2021;22(4):171–6. DOI: [10.5152/alphapsychiatry.2021.21307](https://doi.org/10.5152/alphapsychiatry.2021.21307). PMID: 36424935; PMCID: [PMC9590645](https://pubmed.ncbi.nlm.nih.gov/PMC9590645/)
- Padmanabhan JL, Shah JL, Tandon N, Keshavan MS. The “polyenviromic risk score”: aggregating environmental risk factors predicts conversion to psychosis in familial high-risk subjects. *Schizophr Res*. 2017;181:17–22. DOI: [10.1016/j.schres.2016.10.014](https://doi.org/10.1016/j.schres.2016.10.014). PMID: 28029515; PMCID: [PMC5365360](https://pubmed.ncbi.nlm.nih.gov/PMC5365360/)
- Vassos E, Sham P, Kempton M, Trotta A, Stilo SA, Gayer-Anderson C, et al. The Maudsley environmental risk score for psychosis. *Psychol Med*. 2020;50(13):2213–20. DOI: [10.1017/S0033291719002319](https://doi.org/10.1017/S0033291719002319). PMID: 31535606; PMCID: [PMC7557157](https://pubmed.ncbi.nlm.nih.gov/PMC7557157/)
- Mas S, Boloc D, Rodríguez N, Mezquida G, Amoretti S, Cuesta MJ, et al. Examining gene-environment interactions using aggregate scores in a first-episode psychosis cohort. *Schizophr Bull*. 2020;46(4):1019–25. DOI: [10.1093/schbul/sbaa012](https://doi.org/10.1093/schbul/sbaa012). PMID: 32083289; PMCID: [PMC7342095](https://pubmed.ncbi.nlm.nih.gov/PMC7342095/)
- Pries LK, Lage-Castellanos A, Delespaul P, Kenis G, Luyckx JJ, Lin BD, et al. Estimating exposome score for schizophrenia using predictive modeling approach in two independent samples: the results from the EUGEI study. *Schizophr Bull*. 2019;45(5):960–5. DOI: [10.1093/schbul/sbz054](https://doi.org/10.1093/schbul/sbz054). PMID: 31508804; PMCID: [PMC6737483](https://pubmed.ncbi.nlm.nih.gov/PMC6737483/)
- Zhang H, Khan A, Kushner SA, Rzhetsky A. Dissecting schizophrenia phenotypic variation: the contribution of genetic variation, environmental exposures, and gene-environment interactions. *Schizophrenia (Heidelb)*. 2022;8(1):51. DOI: [10.1038/s41537-022-00257-5](https://doi.org/10.1038/s41537-022-00257-5). PMID: 35853906; PMCID: [PMC9261082](https://pubmed.ncbi.nlm.nih.gov/PMC9261082/)
- Assary E, Vincent JP, Keers R, Pluess M. Gene-environment interaction and psychiatric disorders: review and future directions. *Semin Cell Dev Biol*. 2018;77:133–43. DOI: [10.1016/j.semcdb.2017.10.016](https://doi.org/10.1016/j.semcdb.2017.10.016). PMID: 29051054
- Van Os J, Rutten BP, Poulton R. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. *Schizophr Bull*. 2008;34(6):1066–82. DOI: [10.1093/schbul/sbn117](https://doi.org/10.1093/schbul/sbn117). PMID: 18791076; PMCID: [PMC2632485](https://pubmed.ncbi.nlm.nih.gov/PMC2632485/)



29. Børglum A, Demontis D, Grove J, Pallesen J, Hollegaard MV, Pedersen CB, et al. Genome-wide study of association and interaction with maternal cytomegalovirus infection suggests new schizophrenia loci. *Mol Psychiatry*. 2014;19(3):325–33. DOI: [10.1038/mp.2013.2](https://doi.org/10.1038/mp.2013.2). PMID: 23358160; PMCID: [PMC3932405](https://pubmed.ncbi.nlm.nih.gov/23358160/)
30. Avramopoulos D, Pearce BD, McGrath J, Wolyniec P, Wang R, Eckart N, et al. Infection and inflammation in schizophrenia and bipolar disorder: a genome wide study for interactions with genetic variation. *PLoS One*. 2015;10(3):e0116696. DOI: [10.1371/journal.pone.0116696](https://doi.org/10.1371/journal.pone.0116696). PMID: 25781172; PMCID: [PMC4363491](https://pubmed.ncbi.nlm.nih.gov/25781172/)
31. Benros ME, Trabjerg BB, Meier S, Mattheisen M, Mortensen PB, Mors O, et al. Influence of polygenic risk scores on the association between infections and schizophrenia. *Biol Psychiatry*. 2016;80(8):609–16. DOI: [10.1016/j.biopsych.2016.04.008](https://doi.org/10.1016/j.biopsych.2016.04.008). PMID: 27364036
32. Valli I, Gonzalez Segura A, Verdolini N, Garcia-Rizo C, Berge D, Baeza I, et al. Obstetric complications and genetic risk for schizophrenia: differential role of antenatal and perinatal events in first episode psychosis. *Acta Psychiatr Scand*. 2023;148(1):81–90. DOI: [10.1111/acps.13546](https://doi.org/10.1111/acps.13546). PMID: 36912272
33. Vassos E, Kou J, Tosato S, Maxwell J, Dennison CA, Legge SE, et al. Lack of support for the genes by early environment interaction hypothesis in the pathogenesis of schizophrenia. *Schizophr Bull*. 2022;48(1):20–6. DOI: [10.1093/schbul/sbab052](https://doi.org/10.1093/schbul/sbab052). PMID: 33987677; PMCID: [PMC8781344](https://pubmed.ncbi.nlm.nih.gov/33987677/)
34. Trotta A, Iyegbe C, Di Forti M, Sham PC, Campbell DD, Cherny SS, et al. Interplay between schizophrenia polygenic risk score and childhood adversity in first-presentation psychotic disorder: a pilot study. *PLoS One*. 2016;11(9):e0163319. DOI: [10.1371/journal.pone.0163319](https://doi.org/10.1371/journal.pone.0163319). PMID: 27648571; PMCID: [PMC5029892](https://pubmed.ncbi.nlm.nih.gov/27648571/)
35. Van Os J, Pries L-K, Ten Have M, de Graaf R, van Dorsselaer S, Delespaul P, et al. Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway. *Psychol Med*. 2022;52(10):1910–22. DOI: [10.1017/S0033291720003748](https://doi.org/10.1017/S0033291720003748). PMID: 33070791
36. Pasman JA, Verweij KJH, Gerring Z, Stringer S, Sanchez-Roige S, Treur JL, et al. GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal effect of schizophrenia liability. *Nat Neurosci*. 2018;21(9):1161–70. DOI: [10.1038/s41593-018-0206-1](https://doi.org/10.1038/s41593-018-0206-1). PMID: 30150663; PMCID: [PMC6386176](https://pubmed.ncbi.nlm.nih.gov/30150663/)
37. Johnson EC, Colbert SMC, Jeffries PW, Tillman R, Bigdeli TB, Karcher NR, et al. Associations between cannabis use, polygenic liability for schizophrenia, and cannabis-related experiences in a sample of cannabis users. *Schizophr Bull*. 2023;49(3):778–87. DOI: [10.1093/schbul/sbac196](https://doi.org/10.1093/schbul/sbac196). PMID: 36545904; PMCID: [PMC10154717](https://pubmed.ncbi.nlm.nih.gov/36545904/)
38. Cheng W, Parker N, Karadag N, Koch E, Hindley G, Ick R, et al. The relationship between cannabis use, schizophrenia, and bipolar disorder: a genetically informed study. *Lancet Psychiatry*. 2023;10(6):441–51. DOI: [10.1016/S2215-0366\(23\)00143-8](https://doi.org/10.1016/S2215-0366(23)00143-8). PMID: 37208114; PMCID: [PMC10311008](https://pubmed.ncbi.nlm.nih.gov/37208114/)
39. Maxwell JM, Coleman JRI, Breen G, Vassos E. Association between genetic risk for psychiatric disorders and the probability of living in urban settings. *JAMA Psychiatry*. 2021;78(12):1355–64. DOI: [10.1001/jamapsychiatry.2021.2983](https://doi.org/10.1001/jamapsychiatry.2021.2983). PMID: 34705035; PMCID: [PMC8552117](https://pubmed.ncbi.nlm.nih.gov/34705035/)
40. Sariassan A, Fazel S, D'onofrio BM, Långström N, Larsson H, Bergen SE, et al. Schizophrenia and subsequent neighborhood deprivation: revisiting the social drift hypothesis using population, twin and molecular genetic data. *Transl Psychiatry*. 2016;6(5):e796–6. DOI: [10.1038/tp.2016.62](https://doi.org/10.1038/tp.2016.62). PMID: 27138795; PMCID: [PMC5070045](https://pubmed.ncbi.nlm.nih.gov/27138795/)
41. Pakisarian D, Trabjerg BB, Merikangas KR, Mors O, Børglum AD, McGrath JJ, et al. The role of genetic liability in the association of urbanicity at birth and during upbringing with schizophrenia in Denmark. *Psychol Med*. 2018;48(2):305–14. DOI: [10.1017/S0033291717001696](https://doi.org/10.1017/S0033291717001696). PMID: 28659227; PMCID: [PMC6361630](https://pubmed.ncbi.nlm.nih.gov/28659227/)
42. Guloksuz S, Pries L-K, Delespaul P, Kenis G, Luyck JJ, Lin BD, et al. Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study. *World Psychiatry*. 2019;18(2):173–82. DOI: [10.1002/wps.20629](https://doi.org/10.1002/wps.20629). PMID: 31059627; PMCID: [PMC6502485](https://pubmed.ncbi.nlm.nih.gov/31059627/)
43. Cuesta MJ, Papiol S, Ibañez B, García de Jalón E, Sánchez-Torres AM, Gil-Berrozpe GJ, et al. Effect of polygenic risk score, family load of schizophrenia and exposure risk score, and their interactions, on the long-term outcome of first-episode psychosis. *Psychol Med*. 2023;53(14):6838–47.
44. Pries LK, Dal Ferro GA, van Os J, Delespaul P, Kenis G, Lin BD, et al. Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum. *Epidemiol Psychiatr Sci*. 2020;29:e182. DOI: [10.1017/S2045796020000943](https://doi.org/10.1017/S2045796020000943). PMID: 33200977; PMCID: [PMC7681168](https://pubmed.ncbi.nlm.nih.gov/33200977/)
45. Kendler KS, Gardner CO. Interpretation of interactions: guide for the perplexed. *British J Psychiatry*. 2010;197(3):170–1. DOI: [10.1192/bjp.bp.110.081331](https://doi.org/10.1192/bjp.bp.110.081331). PMID: 20807958
46. Roisman GI, Newman DA, Fraley RC, Haltigan JD, Groh AM, Haydon KC. Distinguishing differential susceptibility from diathesis-stress: recommendations for evaluating interaction effects. *Dev Psychopathol*. 2012;24(2):389–409. DOI: [10.1017/S0954579412000065](https://doi.org/10.1017/S0954579412000065). PMID: 22559121
47. Pingault JB, Allegrini AG, Odigie T, Frach L, Baldwin JR, Rijdsdijk F, et al. Research review: how to interpret associations between polygenic scores, environmental risks, and phenotypes. *J Child Psychology Psychiatry*. 2022;63(10):1125–39. DOI: [10.1111/jcpp.13607](https://doi.org/10.1111/jcpp.13607). PMID: 35347715; PMCID: [PMC9790749](https://pubmed.ncbi.nlm.nih.gov/35347715/)
48. Iyegbe C, Campbell D, Butler A, Ajnakina O, Sham P. The emerging molecular architecture of schizophrenia, polygenic risk scores and the clinical implications for GxE research. *Soc Psychiatry Psychiatr Epidemiol*. 2014;49(2):169–82. DOI: [10.1007/s00127-014-0823-2](https://doi.org/10.1007/s00127-014-0823-2). PMID: 24435092
49. Zheutlin AB, Dennis J, Karlsson Linnér R, Moscati A, Restrepo N, Straub P, et al. Penetrance and pleiotropy of polygenic risk scores for schizophrenia in 106,160 patients across four health care systems. *Am J Psychiatry*. 2019;176(10):846–55. DOI: [10.1176/appi.ajp.2019.18091085](https://doi.org/10.1176/appi.ajp.2019.18091085). PMID: 31416338; PMCID: [PMC6961974](https://pubmed.ncbi.nlm.nih.gov/31416338/)
50. Abdellaoui A, Yengo L, Verweij KJH, Visscher PM. 15 years of GWAS discovery: realizing the promise. *Am J Hum Genet*. 2023;110(2):179–94. DOI: [10.1016/j.ajhg.2022.12.011](https://doi.org/10.1016/j.ajhg.2022.12.011). PMID: 36634672; PMCID: [PMC9943775](https://pubmed.ncbi.nlm.nih.gov/36634672/)
51. Howe LJ, Nivard MG, Morris TT, Hansen AF, Rasheed H, Cho Y, et al. Within-sibship genome-wide association analyses decrease bias in estimates of direct genetic effects. *Nat Genet*. 2022;54(5):581–92. DOI: [10.1038/s41588-022-01062-7](https://doi.org/10.1038/s41588-022-01062-7). PMID: 35534559; PMCID: [PMC9110300](https://pubmed.ncbi.nlm.nih.gov/35534559/)
52. Murray GK, Lin T, Austin J, McGrath JJ, Hickie IB, Wray NR. Could polygenic risk scores be useful in psychiatry?: a review. *JAMA Psychiatry*. 2021;78(2):210–9. DOI: [10.1001/jamapsychiatry.2020.3042](https://doi.org/10.1001/jamapsychiatry.2020.3042). PMID: 33052393
53. Ikeda M, Saito T, Kanazawa T, Iwata N. Polygenic risk score as clinical utility in psychiatry: a clinical viewpoint. *J Hum Genet*. 2021;66(1):53–60. DOI: [10.1038/s10038-020-0814-y](https://doi.org/10.1038/s10038-020-0814-y). PMID: 32770057
54. Bipolar Disorder and Schizophrenia Working Group of the Psychiatric Genomics Consortium; Ruderfer DM, Ripke S, McQuillin A, Boocock J, Stahl EA, et al. Genomic dissection of bipolar disorder and schizophrenia, including 28 subphenotypes. *Cell*. 2018;173(7):1705–1715.e16. DOI: [10.1016/j.cell.2018.05.046](https://doi.org/10.1016/j.cell.2018.05.046). PMID: 29906448; PMCID: [PMC6432650](https://pubmed.ncbi.nlm.nih.gov/29906448/)
55. Murcay CE, Lewinger JP, Gauderman WJ. Gene-environment interaction in genome-wide association studies. *Am J Epidemiol*. 2009;169(2):219–26. DOI: [10.1093/aje/kwn353](https://doi.org/10.1093/aje/kwn353). PMID: 19022827; PMCID: [PMC2732981](https://pubmed.ncbi.nlm.nih.gov/19022827/)
56. Gauderman WJ, Zhang P, Morrison JL, Lewinger JP. Finding novel genes by testing G × E interactions in a genome-wide association study. *Genet Epidemiol*. 2013;37(6):603–13. DOI: [10.1002/gepi.21748](https://doi.org/10.1002/gepi.21748). PMID: 23873611; PMCID: [PMC4348012](https://pubmed.ncbi.nlm.nih.gov/23873611/)
57. Zhang Q, Privé F, Vilhjálmsson B, Speed D. Improved genetic prediction of complex traits from individual-level data or summary statistics. *Nat Commun*. 2021;12(1):4192. DOI: [10.1038/s41467-021-24485-y](https://doi.org/10.1038/s41467-021-24485-y). PMID: 34234142; PMCID: [PMC8263809](https://pubmed.ncbi.nlm.nih.gov/34234142/)
58. Choi SW, García-González J, Ruan Y, Wu HM, Porras C, Johnson J, et al. PRSet: pathway-based polygenic risk score analyses and software. *PLoS Genet*. 2023;19(2):e1010624. DOI: [10.1371/journal.pgen.1010624](https://doi.org/10.1371/journal.pgen.1010624). PMID: 36749789; PMCID: [PMC9937466](https://pubmed.ncbi.nlm.nih.gov/36749789/)
59. Guan F, Ni T, Zhu W, Williams LK, Cui LB, Li M, et al. Integrative omics of schizophrenia: from genetic determinants to clinical classification and risk prediction. *Mol Psychiatry*. 2022;27(1):113–26. DOI: [10.1038/s41380-021-01201-2](https://doi.org/10.1038/s41380-021-01201-2). PMID: 34193973; PMCID: [PMC11018294](https://pubmed.ncbi.nlm.nih.gov/34193973/)
60. Singh T, Poterba T, Curtis D, Akil H, Al Eissa M, Barchas JD, et al. Rare coding variants in ten genes confer substantial risk for schizophrenia. *Nature*. 2022;604(7906):509–16. DOI: [10.1038/s41586-022-04556-w](https://doi.org/10.1038/s41586-022-04556-w). PMID: 35396579; PMCID: [PMC9805802](https://pubmed.ncbi.nlm.nih.gov/35396579/)
61. Beaton EA, Simon TJ. How might stress contribute to increased risk for schizophrenia in children with chromosome 22q11.2 deletion syndrome? *J Neurodev Disord*. 2011;3(1):68–75. DOI: [10.1007/s11689-010-9069-9](https://doi.org/10.1007/s11689-010-9069-9). PMID: 21475728; PMCID: [PMC3056992](https://pubmed.ncbi.nlm.nih.gov/21475728/)
62. Modasi J, Khachadourian V, O'Hara K, Kushan L, Slavich GM, Shields GS, et al. Associations between acute and chronic lifetime stressors and psychosis-risk symptoms in individuals with 22q11.2 copy number variants. *Psychol Med*. 2023;53(15):7222–31. DOI: [10.1017/S0033291723000740](https://doi.org/10.1017/S0033291723000740). PMID: 37078394; PMCID: [PMC10719673](https://pubmed.ncbi.nlm.nih.gov/37078394/)
63. Kendler KS, Neale MC. "Familiality" or heritability. *Arch Gen Psychiatry*. 2009;66(4):452–3. DOI: [10.1001/archgenpsychiatry.2009.14](https://doi.org/10.1001/archgenpsychiatry.2009.14). PMID: 19349315; PMCID: [PMC4028600](https://pubmed.ncbi.nlm.nih.gov/19349315/)
64. Kendler KS, Ohlsson H, Sundquist J, Sundquist K. The patterns of family genetic risk scores for eleven major psychiatric and substance use disorders in a Swedish national sample. *Transl Psychiatry*. 2021;11(1):326. DOI: [10.1038/s41398-021-01454-z](https://doi.org/10.1038/s41398-021-01454-z). PMID: 34045441 PMCID: [PMC8160183](https://pubmed.ncbi.nlm.nih.gov/34045441/)
65. Huijoe ML, Gahal S, Loh P-R, Patterson N, Price AL. Liability threshold modeling of case-control status and family history of disease increases association power. *Nat Genet*. 2020;52(5):541–7. DOI: [10.1038/s41588-020-0613-6](https://doi.org/10.1038/s41588-020-0613-6). PMID: 32313248; PMCID: [PMC7210076](https://pubmed.ncbi.nlm.nih.gov/32313248/)
66. Krebs MD, Hellberg K-LG, Lundberg M, Appadurai V, Ohlsson H, Pedersen E, et al. PA-FGRS is a novel estimator of pedigree-based genetic liability that complements genotype-based inferences into the genetic architecture of major depressive disorder. *medRxiv*. 2023. DOI: [10.1101/2023.06.23.23291611](https://doi.org/10.1101/2023.06.23.23291611)
67. Kendler KS, Ohlsson H, Sundquist J, Sundquist K. Family genetic risk scores and the genetic architecture of major affective and psychotic disorders in a Swedish national sample. *JAMA Psychiatry*. 2021;78(7):735–43. DOI: [10.1001/jamapsychiatry.2021.0336](https://doi.org/10.1001/jamapsychiatry.2021.0336). PMID: 33881469; PMCID: [PMC8060884](https://pubmed.ncbi.nlm.nih.gov/33881469/)
68. Kendler KS, Ohlsson H, Sundquist J, Sundquist K. Relationship of family genetic risk score with diagnostic trajectory in a Swedish national sample of incident cases of major depression, bipolar disorder, other nonaffective psychosis, and schizophrenia. *JAMA Psychiatry*. 2023;80(3):241–9. DOI: [10.1001/jamapsychiatry.2022.4676](https://doi.org/10.1001/jamapsychiatry.2022.4676). PMID: 36696095; PMCID: [PMC9878431](https://pubmed.ncbi.nlm.nih.gov/36696095/)
69. Peterson RE, Kuchenbaecker K, Walters RK, Chen CY, Popejoy AB, Periyasamy S, et al. Genome-wide association studies in ancestrally diverse populations: opportunities, methods, pitfalls, and recommendations. *Cell*. 2019;179(3):589–603. DOI: [10.1016/j.cell.2019.08.051](https://doi.org/10.1016/j.cell.2019.08.051). PMID: 31607513; PMCID: [PMC6939869](https://pubmed.ncbi.nlm.nih.gov/31607513/)
70. Lam M, Chen C-Y, Li Z, Martin AR, Bryois J, Ma X, et al. Comparative genetic architectures of schizophrenia in East Asian and European populations. *Nat Genet*. 2019;51(12):1670–8. DOI: [10.1038/s41588-019-0512-x](https://doi.org/10.1038/s41588-019-0512-x). PMID: 31740837; PMCID: [PMC6885121](https://pubmed.ncbi.nlm.nih.gov/31740837/)
71. Miettinen J, Suvisaari J, Haukka J, Isohanni M. Use of register data for psychiatric epidemiology in the Nordic countries. In: Tsuang MT, Tohen M, Jones PB, eds. *Textbook of Psychiatric Epidemiology*. Chichester, UK: John Wiley & Sons Ltd; 2011;117–31. DOI: [10.1002/9780470976739.ch8](https://doi.org/10.1002/9780470976739.ch8)
72. Bergen SE, Sullivan PF. National-scale precision medicine for psychiatric disorders in Sweden. *Am J Med Genet B Neuropsychiatr Genet*. 2018;177(7):630–4. DOI: [10.1002/ajmg.b.32562](https://doi.org/10.1002/ajmg.b.32562). PMID: 28686353



Publisher's note: Genomic Press maintains a position of impartiality and neutrality regarding territorial assertions represented in published materials and affiliations of institutional nature. As such, we will use the affiliations provided by the authors, without editing them. Such use simply reflects what the authors submitted to us and it does not indicate that Genomic Press supports any type of territorial assertions.



Open Access. This article is licensed to Genomic Press under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). The license mandates: (1) Attribution: Credit must be given to the original work, with a link to the license and notification of

any changes. The acknowledgment should not imply licensor endorsement. (2) Non-Commercial: The material cannot be used for commercial purposes. (3) NoDerivatives: Modified versions of the work cannot be distributed. (4) No additional legal or technological restrictions may be applied beyond those stipulated in the license. Public domain materials or those covered by statutory exceptions are exempt from these terms. This license does not cover all potential rights, such as publicity or privacy rights, which may restrict material use. Third-party content in this article falls under the article's Creative Commons license unless otherwise stated. If use exceeds the license scope or statutory regulation, permission must be obtained from the copyright holder. For complete license details, visit <https://creativecommons.org/licenses/by-nc-nd/4.0/>. The license is provided without warranties.